The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Izmailov S.G.

Berezov City Clinical Hospital No. 7, Leninsky District of the Nizhny Novgorod Region

Lukoyanychev E.E.

Berezov City Clinical Hospital No. 7, Leninsky District of the Nizhny Novgorod Region

Parshikov V.V.

Privolzhsky Research Medical University

Dobrokvashin S.V.

Kazan State Medical University

Izmailov A.G.

Kazan State Medical University

Regenerative modulators use in the surgical treatment of anterior abdominal wall hernias

Authors:

Izmailov S.G., Lukoyanychev E.E., Parshikov V.V., Dobrokvashin S.V., Izmailov A.G.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2025;14(1): 63‑70

DOI: 10.17116/dokgastro20251401163

Read: 943 times

Download PDF (RU)
Contact the author
Table of contents

REGENERATIVE MODULATORS USE IN THE SURGICAL TREATMENT OF ANTERIOR ABDOMINAL WALL HERNIAS
REGENERATIVE MODULATORS USE IN THE SURGICAL TREATMENT OF ANTERIOR ABDOMINAL WALL HERNIAS

To cite this article:

Izmailov SG, Lukoyanychev EE, Parshikov VV, Dobrokvashin SV, Izmailov AG. Regenerative modulators use in the surgical treatment of anterior abdominal wall hernias. Russian Journal of Evidence-Based Gastroenterology. 2025;14(1):63‑70. (In Russ.)
https://doi.org/10.17116/dokgastro20251401163

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Simu­ltaneous auto­plastic repair and diastasis recti correction for linea alba hernias. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):34-39
Iatrogenic exte­rnal iliac artery injury following inguinal hernia repair. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):695-698
Evolution of surgical methods for correction of pelvic organ prolapse. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):31-36
Stru­ctural and functional tissue response to implants in patients with recu­rrent abdo­minal wall hernias in long-term period. Piro­gov Russian Journal of Surgery. 2025;(4):39-45
Rela­pses after surgical treatment of pelvic organ prolapse in women with connective tissue dysplasia. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):93-97
Use of xeno­genic biomaterials in gyne­cologic practice of pelvic organ prolapse correction. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):50-56
Anatomical and clinical substantiation of endo­videosurgical extraperitoneal hernioplasty using the TEP technique. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2-2):87-94
Inguinal hernia repair: standardized lapa­roscopic transabdominal preperitoneal repair. Methodology for deve­loping intraoperative algo­rithms. Endo­scopic Surgery. 2025;(4):13-18
“Classical” sacrocolpopexy as a method of surgical correction of apical geni­tal prolapse. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):92-97
Abstract:

Hernias of the anterior abdominal wall remain a significant challenge in surgery due to the high rate of postoperative complications. One promising approach to improving patient outcomes involves the use of regeneration modulators, such as pyrimidine derivatives. This article examines the mechanisms of action and clinical potential of pyrimidine-based drugs, including hydroxyethyldimethyldihydropyrimidine (xymedon), in hernioplasty.

KEY POINTS

Pyrimidine derivatives, including xymedon, offer a broad range of pharmacological effects, such as wound-healing, anti-inflammatory, and immunostimulatory properties. Xymedon has been shown to reduce levels of inflammatory cytokines and acute-phase proteins, enhance tissue proliferation and angiogenesis, and regulate collagen synthesis. Clinical studies indicate that using xymedon following prosthetic hernioplasty decreases the incidence of complications (e.g., seroma and hematoma) and promotes improved wound healing.

CONCLUSION

Regeneration modulators, particularly xymedon, show promise in the surgical treatment of anterior abdominal wall hernias by optimizing the interaction between implants and surrounding tissues. These agents mitigate inflammatory responses, expedite regenerative processes, and enhance tissue resistance to infections. Further research is warranted to refine their clinical applications and broaden their indications.

Keywords:

hernioplasty
mesh implants
pyrimidine derivatives
xymedon
tissue regeneration

Authors:

Izmailov S.G.

Berezov City Clinical Hospital No. 7, Leninsky District of the Nizhny Novgorod Region

Lukoyanychev E.E.

Berezov City Clinical Hospital No. 7, Leninsky District of the Nizhny Novgorod Region

Parshikov V.V.

Privolzhsky Research Medical University

Dobrokvashin S.V.

Kazan State Medical University

Izmailov A.G.

Kazan State Medical University

Received:

23.01.2025

Accepted:

27.01.2025

Close metadata

References:

  1. Morozov AM, Sergeev AN, Sergeev NA, Ryzhova TS, Pakhomov MA. Diagnosis and prophylaxis of infectious complications in the surgical intervention zone. Vestnik Ivanovskoj meditsinskoj akademii. 2021;26(1):54-58. (In Russ.).
  2. Lukoyanychev EE, Izmailov SG, Evsyukov DA, Leont’ev AE, Nikol’skij VO, Mironov AA, Panyushkin AV, Firsova AO. Pharmacological Regulation of the Inflammatory Response under Mesh Implant Prosthetics in the Treatment of Patients with External Abdominal Hernias. Vestnik eksperimental’noj i klinicheskoj khirurgii. 2022;15(2):122-130. (In Russ.). https://doi.org/10.18499/2070-478X-2022-15-2-122-130
  3. Parshikov VV. Inflammatory Complications of the Abdominal Wall Prosthetic Repair: Diagnostics, Treatment, and Prevention (Review). Sovremennye tekhnologii v meditsine. 2019;11(3):158-178. (In Russ.). https://doi.org/10.17691/stm2019.11.3.19
  4. Stupin VA, Dzhfarov ET, Chernyakov AV, Krott E, Klinge U, Anurov MV, Polivoda MD, Titkova SM, Oettinger AP. Special features of connective tissue in patients with incisional ventral hernias. Vestnik RGMU. 2009;(5):7-10. (In Russ.).
  5. Lukoyanychev EE, Izmailov SG, Mironov AA, Izmailov AG, Bodrov AA, Bogdanov SN, Kolchina OS, Mel’nik SA, Evsyukov DA, Vadyaeva TV. Pharmacological stimulation of mesh implant engraftment after ventral hernia repair. Kazanskij meditsinskij zhurnal. 2021;102(1):6-11. (In Russ.). https://doi.org/10.17816/KMJ2021-6
  6. Izmailov SG, Izmailov GA, Aver’yanov MYU, Reznik VS. Ksimedon v klinicheskoj praktike. N. Novgorod: NGMA; 2001. (In Russ.).
  7. Mashkovsky MD. Lekarstvennye sredstva. M.: Novaya volna; 2021. (In Russ.).
  8. Plecheva DV, Okroyan VP, Ibragimov TR, Galimov OV, Khanov VO. Improvement of reparative regeneration in surgery. Permskij meditsinskij zhurnal. 2018;35(3):32-38. (In Russ.). https://doi.org/10.17816/pmj35332-38
  9. Studentsov EP, Ramsh SM, Kazurova NG, Neporozhneva OV, Garabadzhiu AV, Kochina TA, Voronkov MG, Kuznetsov VA, Krivorotov DV. Adaptogens and Related Groups of Drugs — 50 Years of Searching. Obzory po klinicheskoj farmakologii i lekarstvennoj terapii. 2013;11(4):3-43. (In Russ.). https://doi.org/10.17816/RCF1143-43
  10. Chulkina MM, Lebedeva ES, Pichugin AV, Kholmukhamedov EL, Atallakhanov RI. Regeneration-inducing tetradecapeptide activates mapk-kinase signaling in NIH/3T3 fibroblasts. Immunologiya. 2017;38(4):172-179. (In Russ.).
  11. Kadyrov MA, Ashiraliev Zh. Optimal solution for infusion therapy in the early postoperative period in children. Ekonomika i sotsium. 2023;107(4):659-667. (In Russ.).
  12. Uruzbaev RM, Silant’eva TA, Gorbach EN, Bychkov VG, Yuzhakova EA. Regenerative properties of tissues and organs, factors of improvement of regenerative processes (review). Meditsinskaya nauka i obrazovanie Urala. 2017;18(1):171-178. (In Russ.).
  13. Samotrueva MA, Tsibizova AA, Yasenyavskaya AL, Ozerov AA, Tyurenkov IN. Pharmacological activity of pyrimidine derivatives. Astrakhanskij meditsinskij zhurnal. 2015;10(1):12-29. (In Russ.).
  14. Izmailov AG. Derivatives of pyrimidine in surgical practice. Sovremennaya meditsina. 2018;10(2):177-182. (In Russ.).
  15. Dobrokvashin SV, Izmailov AG, Shakirova DKh, Vasil’kin DA. Primenenie preparata ksimedon v khirurgicheskoj praktike (Prakticheskie rekomendatsii). Kazan; 2017. (In Russ.).
  16. Reznik VS, Pashkurov NG. Interaction of hydroxy and mercaptopyrimidines with ethylene and propylene chlorohydrins. Izvestiya AN SSSR. Seriya khimicheskaya. 1966;91:13. (In Russ.).
  17. Vlasov SV, Kovalenko SN, Osolodchenko TP, Lenitskaya EB, Chernykh VP. Synthesis and biological activity of 6-(1,3-benzoxazol-2-yl)-5-methylthieno[2,3-d]pyrimidines. Khimiko-farmatsevticheskij zhurnal. 2018;52(6):22-25. (In Russ.). https://doi.org/10.30906/0023-1134-2018-52-6-22-25
  18. Larionov MV. The effect of xymedon and local ozone therapy on the clinical course of chronic venous insufficiency of the lower extremities in the decompensation stage. Bioradikaly i antioksidanty. 2021;8(3):26-36. (In Russ.).
  19. Izmailov SG, Parshikov VV. Ximedon: Present and Future. Nizhegorodskij meditsinskij zhurnal. 2002;(3):81-87. (In Russ.).
  20. Dobrokvashin SV, Volkov DE, Izmailov AG. Treatment and diagnostic tactics for ulcerative gastroduodenal bleeding. Prakticheskaya meditsina. 2013;67(2):21-27. (In Russ.).
  21. Izmailov SG, Lukoyanychev EE, Izmailov AG, Timofeev EP, Leont’ev AE. Farmakologicheskie i operativno-instrumental’nye tekhnologii stimulyatsii reparatsii tkanej v khirurgii. N. Novgorod: NGTU im. R.E. Alekseeva; 2024. (In Russ.).
  22. Slabnov YuD, Valimukhametova DA, Valeeva IKh, Garaev RS. The influence of pyrimidine derivatives — xymedone and diucifon on the bioenergetic processes of mitochondria. Kazanskij meditsinskij zhurnal. 1996;(3):179-181. (In Russ.).
  23. Zinatulina GM, Faizullina EV, Fazylov VKh, Vasil’kin DA. Features of the immune status in patients with microbial eczema and erysipelas: a method of therapeutic correction. Vestnik dermatologii i venerologii. 2016;92(2):87-95. (In Russ.). https://doi.org/10.25208/0042-4609-2016-92-2-87-95
  24. Panteleev DA, Mel’nikova NB. Physicochemical, pharmacological and biological properties of xymedon in hydrophilic gels and ointments for the treatment of purulent burn wounds. Bioradikaly i antioksidanty. 2021;8(4):26-36. (In Russ.).
  25. Izmailov AG, Dobrokvashin SV, Volkov DE, Pyrkov VA, Zakirov RF, Davlet-Kil’deev ShA, Akhmetzyanov RF. Patient selection for anterior abdominal wall hernias surgery with postoperative wound complications prevention. Vestnik sovremennoj klinicheskoj meditsiny. 2019;12(5):30-34. (In Russ.). https://doi.org/10.20969/VSKM.2019.12(5).30-34
  26. Kochnev OS, Izmailov SG. The use of xymedon to stimulate healing and prevent suppuration of postoperative wounds. Khirurgiya. 1991;(5):27-30. (In Russ.).
  27. Izmailov SG, Lukoyanychev EE, Spiridonov VI, Panyushkin AV, Morozova AI, Bagryantsev MV, Emel’yanov VA. Instrumental-pharmacological combination in the prevention of wound infection in emergency abdominal surgery. Zabaikal’skij meditsinskij vestnik. 2019;(1):135-143. (In Russ.). https://doi.org/10.52485/19986173_2019_1_135
  28. Izmailov SG, Gorbunov SM, Izmailov GA. Preclinical study of xymedon. Antibiotiki i khimioterapiya. 1999;(8):12-17. (In Russ.).
  29. Izmailov SG, Izmailov GA, Podushkina IV, Garaev VN, Kedrin MYu, Gorbunov SM, Tereshchenko VYu, Reznik VS, Izmailov AG, Lazarev VM, Muslinkin AA, Evranova GB, Gerasimova MKh, Bodrov AA. Acceleration of wound healing under the influence of a new pyrimidine drug xymedon. Kazanskij meditsinskij zhurnal. 2000;81(5):422-427. (In Russ.). https://doi.org/10.17816/kazmj96447
  30. Parshikov VV, Mironov AA, Anikina EA, Zaslavskaya MI, Alekhin AI, Kazantsev AA. Prosthetic Repair of the Abdominal Wall Using Light and Ultra-Light synthetic and Titan-Containing Materials in High bacterial Contamination (Experimental study). Sovremenny`e texnologii v medicine. 2015;7(4):64-71. (In Russ.). https://doi.org/10.17691/stm2015.7.4.08
  31. Izmailov SG, Lukoyanychev EE, Leont’ev AE, Bodrov AA, Rotkov AI, Koloshein NA. Prophylactic “Xymedon” in Abdominal Surgery. Vestnik eksperimental’noj i klinicheskoj khirurgii. 2021;14(2):152-160. (In Russ.). https://doi.org/10.18499/2070-478X-2021-14-2-152-160
  32. Kokotovic D, Burcharth J, Helgstrand F, Gögenur I. Systemic inflammatory response after hernia repair: a systematic review. Langenbecks Archives of Surgery. 2017;402 (7):1023-1037. https://doi.org/10.1007/s00423-017-1618-1
  33. Samartsev VA, Gavrilov VA, Parshakov AA, Kuznetsova MV. Posterior separation hernioplasty TAR in treatment for postoperative ventral hernias W3. Permskij meditsinskij zhurnal. 2017;34(1):35-42. (In Russ.).
  34. Belokonev VI, Ponomareva YuV, Pushkin SYu, Melent’eva ON, Gulyaev MG. Possible predictors and morphological aspects of seroma development after plastic surgery of anterior abdominal wall hernia. Novosti khirurgii. 2014;22(6):665-670. (In Russ.). https://doi.org/10.18484/2305-0047.2014.6.665
  35. Pochhammer J, Scholtes B, Keuler J, Müssle B, Welsch T, Schäffer M. Serum C-reactive Protein Level After Ventral Hernia Repair With Mesh Reinforcement Can Predict Infectious Complications: A Retrospective Cohort Study. Hernia. 2020;24(1):41-48.  https://doi.org/10.1007/s10029-018-1844-7
  36. Degovtsov EN, Kolyadko PV. Diagnosis and treatment of seroma after anterior abdominal wall hernia repair by using of mesh implant. Pirogov Russian Journal of Surgery. 2018;(1):99-102. (In Russ.). https://doi.org/10.17116/hirurgia2018199-102
  37. Poelman MM, Schellekens JF, Langenhorst BL, Schreurs WH. Health-related quality of life in patients treated for incisional hernia with an onlay technique. Hernia. 2010;14(3):237-242.  https://doi.org/10.1007/s10029-009-0619-6
  38. Sahoo S, Haskins IN, Huang LC, Krpata DM, Derwin KA, Poulose BK, Rosen MJ. Early wound morbidity after open ventral hernia repair with biosynthetic or polypropylene mesh. Journal of the American College of Surgeons. 2017;225(4):472-480.  https://doi.org/10.1016/j.jamcollsurg.2017.07.1067
  39. Canakci E, Cihan M, Altinbas A, Cebeci Z, Gultekin A, Tas N. Efficacy of ultrasound-guided Transversus Abdominis Plane (TAP) block in inguinal hernia surgery and the immunomodulatory effects of proinflammatory cytokines: prospective, randomized, placebocontrolled study. Brazilian Journal of Anesthesiology. 2021;71(5):538-544.  https://doi.org/10.1016/j.bjane.2021.02.005
  40. Sartelli M, Coccolini F, van Ramshorst GH, Campanelli G, Mandalà V, Ansaloni L, Moore EE, Peitzman A, Velmahos G, Moore FA, Leppaniemi A, Burlew CC, Biffl W, Koike K, Kluger Yo, Fraga GP, Ordonez CA, Saverio SD, Agresta F, Sakakushev B, Gerych I, Wani I, Kelly MD, Gomes CA, Faro MP Jr, Taviloglu K, Demetrashvili Z, Lee JG, Vettoretto N, Guercioni G, Tranà C, Cui Yu, Kok KYY, Ghnnam WM, Abbas AES, Sato N, Marwah S, Rangarajan M, Offir Ben-Ishay, Adesunkanmi ARK, Segovia Lohse HA, Kenig J, Mandalà S, Patrizi A, Scibé R, Catena F. WSES guidelines for emergency repair of complicated abdominal wall hernias. World Journal of Emergency Surgery. 2013; 8(1):50.  https://doi.org/10.1186/1749-7922-8-50
  41. Bosanquet DC, Ansell J, Abdelrahman T, Cornish J, Harries R, Stimpson A, Davies L, Glasbey JCD, Frewer KA, Frewer NC, Russell D, Russell I, Torkington J. Systematic Review and Meta-Regression of Factors Affecting Midline Incisional Hernia Rates: Analysis of 14,618 Patients. PLoS One. 2015;10(9):e0138745. https://doi.org/10.1371/journal.pone.0138745
  42. Lukoyanychev EE, Izmajlov SG, Leontev AE, Mironov AA, Nikolskij VO, Evsjukov DA, Emelyanov VA. Pharmacological support in the perioperative period of implantation of a polypropylene mesh prosthesis (experimental study). Issledovaniya i praktika v meditsine. 2022;9(1):91-102. (In Russ.). https://doi.org/10.17709/2410-1893-2022-9-1-8
  43. Lukoyanychev EE, Izmailov SG, Evsyukov DA, Nikolskij VO, Mironov AA, Panyushkin AV. Possibilities of regulating the reaction of tissues of the implantation area with pyrimidine preparations after prosthetic repair of the hernia ring in the experiment. Issledovaniya i praktika v meditsine. 2022;9(4):83-95. (In Russ.). https://doi.org/10.17709/2410-1893-2022-9-4-8
  44. Lukoyanychev EE, Izmailov SG, Evsyukov DA, Bodrov AA, Rotkov AI, Panyushkin AV. Possibilities of influence on the systemic level of inflammation in the acute phase after prosthetic plastic surgery of the abdominal wall plasty. Vestnik Natsional’nogo mediko-khirurgicheskogo tsentra im. N.I. Pirogova. 2022;17(3):53-58. (In Russ.). https://doi.org/10.25881/20728255_2022_17_3_53
  • Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology. 2022;33(9):959-967.  https://doi.org/10.1016/j.annonc.2022.05.518
  • Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China. European Journal of Cancer. 2014;50(10):1772-1778. https://doi.org/10.1016/j.ejca.2014.03.280
  • McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC. A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. Annals of Surgical Oncology. 2009;16(4):910-919.  https://doi.org/10.1245/s10434-008-0177-7
  • Corless CL, Ballman KV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, von Mehren M, Maki RG, Pisters PW, DeMatteo RP. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. Journal of Clinical Oncology. 2010;28(15 Suppl):10006-10006. https://doi.org/10.1200/jco.2010.28.15_suppl.10006
  • Cousin S. A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE). Accessed August 20, 2024. https://clinicaltrials.gov/study/NCT03475953#more-information
  • Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib. Accessed August 20, 2024. https://clinicaltrials.gov/study/NCT0440922
  • Cogent Biosciences. (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors. Accessed August 20, 2024. https://clinicaltrials.gov/ct2/show/NCT05208047
  • Matsumoto S, Takayama T, Wakatsuki K, Enomoto K, Tanaka T, Migita K, Takano M, Nakajima Y. An esophageal gastrointestinal stromal tumor with regional lymph node metastasis. Esophagus. 2010;7(2):115-118.  https://doi.org/10.1007/s10388-010-0231-y
  • Koyanagi K, Nakagawa M, Ozawa S, Nagase T, Seishima R, Kanai T. Thoracoscopic enucleation for small-sized gastrointestinal stromal tumor of the esophagus: report of two cases. Esophagus. 2010;7(4):219-224.  https://doi.org/10.1007/s10388-010-0243-7
  • Masuda T, Toh Y, Kabashima A, Aoki Y, Harimoto N, Ito S, Taomoto J, Ikeda O, Ohga T, Adachi E, Sakaguchi Y, Hirahashi M, Nishiyama K, Okamura T. Overt lymph node metastases from a gastrointestinal stromal tumor of the esophagus. Journal of Thoracic and Cardiovascular Surgery. 2007;134(3):810-811.  https://doi.org/10.1016/j.jtcvs.2007.06.002
  • Kobayashi H, Kiguchi G, Miki A, Uryuhara K, Okada N, Kaihara S, Imai Y, Hosotani R. A case report of giant esophageal gastrointestinal stromal tumor surgically resected after preoperative imatinib treatment. Esophagus. 2011;8(2):119-124.  https://doi.org/10.1007/s10388-011-0264-x
  • Sato H, Kanda T, Hirota S, Bamba T, Sakamoto K, Kosugi SI, Matsuki A, Mashima Y, Watanabe G, Hatakeyama K. Surgical resection of gastrointestinal stromal tumor of esophagus following preoperative imatinib treatment: a case report. Esophagus. 2010;7(1):65-69.  https://doi.org/10.1007/s10388-009-0217-9
  • Miettinen M, Sobin LH, Lasota J. Gastrointestinal Stromal Tumors of the Stomach. American Journal of Surgical Pathology. 2005;29(1):52-68.  https://doi.org/10.1097/01.pas.0000146010.92933
  • Luo Y, Wu Y, Chang X, Huang B, Luo D, Zhang J, Zhang P, Shi H, Fan J, Nie X. Identification of a novel FGFR2-KIAA1217 fusion in esophageal gastrointestinal stromal tumours: A case report. Frontiers in Oncology. 2022;12.  https://doi.org/10.3389/fonc.2022.884814
  • Haller F, Moskalev EA, Faucz FR, Barthelmeß S, Wiemann S, Bieg M, Assie G, Bertherat J, Schaefer IM, Otto C, Rattenberry E, Maher ER, Ströbel P, Werner M, Carney JA, Hartmann A, Stratakis CA, Agaimy A. Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocrine-Related Cancer. 2014;21(4):567-577.  https://doi.org/10.1530/ERC-14-0254
  • Zhang L, Smyrk TC, Young WF, Stratakis CA, Carney JA. Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases. American Journal of Surgical Pathology. 2010;34(1):53-64.  https://doi.org/10.1097/PAS.0b013e3181c20f4f
  • Ricci R, Martini M, Cenci T, Carbone A, Lanza P, Biondi A, Rindi G, Cassano A, Larghi A, Persiani R, Larocca LM. PDGFRA-mutant syndrome. Modern Pathology. 2015;28(7):954-964.  https://doi.org/10.1038/modpathol.2015.56
  • Arita A, Takahashi T, Nakajima K, Kurokawa Y, Hirota S, Nishida T, Yamashita K, Saito T, Tanaka K, Makino T, Yamasaki M, Kawai K, Motoyama Y, Morii E, Eguchi H, Doki Y. Surgery for multiple gastric gastrointestinal stromal tumors and large esophageal diverticulum related to germline mutation of the KIT gene: a case report. Surgical Case Reports. 2023;9(1):183.  https://doi.org/10.1186/s40792-023-01766-w
  • Bachet JB, Landi B, Laurent-Puig P, Italiano A, Le Cesne A, Lévy P, Safar V, Duffaud F, Blay JY, Emile JF. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. European Journal of Cancer. 2013;49(11):2531-2541. https://doi.org/10.1016/j.ejca.2013.04.005
  • Ohshima K, Fujiya K, Nagashima T, Ohnami S, Hatakeyama K, Urakami K, Naruoka A, Watanabe Y, Moromizato S, Shimoda Y, Ohnami S, Serizawa M, Akiyama Y, Kusuhara M, Mochizuki T, Sugino T, Shiomi A, Tsubosa Y, Uesaka K, Terashima M, Yamaguchi K. Driver gene alterations and activated signaling pathways toward malignant progression of gastrointestinal stromal tumors. Cancer Science. 2019;110(12):3821-3833. https://doi.org/10.1111/cas.14202
  • Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014;120(15):2325-2333. https://doi.org/10.1002/cncr.28669
  • Rubió-Casadevall J, Borràs JL, Carmona-García MC, Ameijide A, Gonzalez-Vidal A, Ortiz MR, Bosch R, Riu F, Parada D, Martí E, Miró J, Sirvent JJ, Galceran J, Marcos-Gragera R. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study. World Journal of Surgical Oncology. 2015;13(1):47.  https://doi.org/10.1186/s12957-015-0474-0
  • Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, Sufliarsky J, Federico M, Jonasson JG, Hostein I, Bringuier PP, Emile JF. KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence. Journal of Clinical Oncology. 2015;33(6):634-642.  https://doi.org/10.1200/JCO.2014.57.4970
  • Park JW, Cho CH, Jeong DS, Chae HD. Role of 18F-fluoro-2-deoxyglucose Positron Emission Tomography in Gastric GIST: Predicting Malignant Potential Pre-operatively. Journal of Gastric Cancer. 2011;11(3):173-179.  https://doi.org/10.5230/jgc.2011.11.3.173
  • Dendy M, Johnson K, Boffa DJ. Spectrum of FDG uptake in large (>10 cm) esophageal leiomyomas. Journal of Thoracic Disease. 2015;7(12):E648-E651. https://doi.org/10.3978/j.issn.2072-1439.2015.11.64
  • Săftoiu A. Endoscopic ultrasound-guided fine needle aspiration biopsy for the molecular diagnosis of gastrointestinal stromal tumors: shifting treatment options. Journal of Gastrointestinal and Liver Diseases. 2008;17(2):131-133. 
  • Lott S, Schmieder M, Mayer B, Henne-Bruns D, Knippschild U, Agaimy A, Schwab M, Kramer K. Gastrointestinal stromal tumors of the esophagus: evaluation of a pooled case series regarding clinicopathological features and clinical outcome. American Journal of Cancer Research. 2015;5(1):333-343. 
  • Stelow EB, Stanley MW, Lai R, Mallery S. Endoscopic Ultrasound-Guided Fine-Needle Aspiration Findings of Gastrointestinal Leiomyomas and Gastrointestinal Stromal Tumors. American Journal of Clinical Pathology. 2003;119(5):703-708.  https://doi.org/10.1309/UWUV-Q001-0D9W-0HPN
  • Nemeth K, Williams C, Rashid M, Robinson M, Rasheed A. Oesophageal GIST—A rare breed case report and review of the literature. International Journal of Surgery Case Reports. 2015;10: 256-259.  https://doi.org/10.1016/j.ijscr.2015.02.023
  • Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245-266.  https://doi.org/10.1111/j.1365-2559.2008.02977.x
  • Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, DeMatteo RP. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. The Lancet Oncology. 2009;10(11):1045-1052. https://doi.org/10.1016/S1470-2045(09)70242-6
  • Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, Sygut J, Chosia M, Rys J, Urbanczyk K, Kruszewski W, Sowa P, Siedlecki J, Debiec-Rychter M, Limon J; Polish Clinical GIST Registry. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Annals of Oncology. 2012;23(2):353-360.  https://doi.org/10.1093/annonc/mdr127
  • Yamamoto H, Ebihara Y, Tanaka K, Matsui A, Nakanishi Y, Asano T, Noji T, Kurashima Y, Murakami S, Nakamura T, Tsuchikawa T, Okamura K, Shichinohe T, Hirano S. Robot-assisted thoracoscopic esophagectomy for gastrointestinal stromal tumor of the esophagus: A case report. International Journal of Surgery Case Reports. 2021;86:106335. https://doi.org/10.1016/j.ijscr.2021.106335
  • Marqueen KE, Moshier E, Buckstein M, Ang C. Neoadjuvant therapy for gastrointestinal stromal tumors: A propensity score‐weighted analysis. International Journal of Cancer. 2021;149(1):177-185.  https://doi.org/10.1002/ijc.33536
  • Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL. Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology. 2012;19(4):1074-1080. https://doi.org/10.1245/s10434-011-2190-5
  • Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T, Hirota S. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib‐resistant gastrointestinal stromal tumor. Cancer Science. 2008;99(4):799-804.  https://doi.org/10.1111/j.1349-7006.2008.00727.x
  • Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clinical Cancer Research. 2005;11(11):4182-4190. https://doi.org/10.1158/1078-0432.CCR-04-2245
  • See full prescribing information for VITRAKVI. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf
  • US Food and Drug Administration. Prescribing information — Rozlytrek. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf
  • Yebra M, Bhargava S, Kumar A, Burgoyne AM, Tang CM, Yoon H, Banerjee S, Aguilera J, Cordes T, Sheth V, Noh S, Ustoy R, Li S, Advani SJ, Corless CL, Heinrich MC, Kurzrock R, Lippman SM, Fanta PT, Harismendy O, Metallo C, Sicklick JK. Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. Clinical Cancer Research. 2022;28(1):187-200.  https://doi.org/10.1158/1078-0432.CCR-21-2092
  • Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST). Accessed September 10, 2024. https://clinicaltrials.gov/study/NCT03556384
  • Dhillon S. Ripretinib: First Approval. Drugs. 2020;80(11):1133-1138. https://doi.org/10.1007/s40265-020-01348-2
  • See full prescribing information for QINLOCK. Accessed September 10, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf
  • US Food and Drug Administration. FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. Accessed September 10, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation
  • Chi P, Qin LX, Nguyen B, Kelly CM, D’Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology. 2022;40(9):997-1008. https://doi.org/10.1200/JCO.21.02029
  • US National Library of Medicine. A study of pimitespib in combination with imatinib in patients with GIST (CHAPTER-GIST-101). Accessed September 10, 2024. https://www.clinicaltrials.gov/ct2/show/NCT05245968
  • Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. British Journal of Cancer. 2017;117(9):1278-1285. https://doi.org/10.1038/bjc.2017.290
  • Adis insight. Gastrointestinal stromal tumours. Accessed September 10, 2024. https://adisinsight.springer.com/drugs/800063657
  • US National Library of Medicine. A phase I/II study of regorafenib plus avelumab in solid tumors (REGOMUNE). Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT03475953
  • US National Library of Medicine. PDR001 plus imatinib for metastatic or unresectable GIST. Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT03609424
  • Call J, Walentas C, Eickhoff JC, Scherzer N. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. BMC Cancer. 2012;12(1):90.  https://doi.org/10.1186/1471-2407-12-90
  • Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Seminars in Diagnostic Pathology. 2006;23(2):70-83.  https://doi.org/10.1053/j.semdp.2006.09.001
  • IJzerman NS, van Werkhoven E, Mohammadi M, Hollander DD, Bleckman RF, Reyners AKL, Desar IME, Gelderblom H, Grünhagen DJ, Mathijssen RHJ, Steeghs N, van der Graaf WTA. Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival? ESMO Open. 2022;7(6):100649. https://doi.org/10.1016/j.esmoop.2022.100649
  • Volchenko NS, Mamontov AS, Goeva NS. Rare esophageal tumors. Onkologiya. P.A. Herzen Journal of Oncology. 2019;8(6):453.  https://doi.org/10.17116/onkolog20198061453
  • Cohen C, Pop D, Icard P, Berthet JP, Venissac N, Mouroux J. Is There a Place for Thoracoscopic Enucleation of Esophageal Gastrointestinal Stromal Tumors? The Thoracic and Cardiovascular Surgeon. 2019;67(07):585-588.  https://doi.org/10.1055/s-0038-1670662
  • Keung EZ, Raut CP. Management of Gastrointestinal Stromal Tumors. Surgical Clinics of North America. 2017;97(2):437-452.  https://doi.org/10.1016/j.suc.2016.12.001
  • Gronchi A, Raut CP. The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones. Annals of Surgical Oncology. 2012;19(4): 1051-1055. https://doi.org/10.1245/s10434-011-2191-4
  • Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors. Journal of Clinical Oncology. 2006;24(15):2325-2331. https://doi.org/10.1200/JCO.2005.05.3439
  • Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulières D, Swallow CJ, Verma S; Canadian Advisory Committee on GIST. Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment. Canadian Journal of Gastroenterology. 2006;20(3):157-163.  https://doi.org/10.1155/2006/434761
  • DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Annals of Surgery. 2007;245(3):347-352.  https://doi.org/10.1097/01.sla.0000236630.93587.59
  • Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nature Reviews Clinical Oncology. 2022;19(5):328-341.  https://doi.org/10.1038/s41571-022-00606-4
  • A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Accessed September 10, 2024. https://meetings.asco.org/abstracts-presentations/208008
  • DS-6157a in Participants with Advanced Gastrointestinal Stromal Tumor (GIST). Accessed September 10, 2024. https://clinicaltrials.gov/ct2/show/NCT04276415
    • Contact the author
    Email
    Message
    The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

    Email Confirmation

    An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

    Email Confirmation

    Contact us
    If you have any questions, complaints or suggestions, please use this feedback form.
    Email
    Message
    The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
    Submit Application

    You can become an author of one of our magazines, send a request and we will consider it in during the day.

    Name
    Phone
    E-mail
    Message
    Login
    Registration
    E-mail
    Password
    Forgot Password?

    Log in to the site using your account in one of the services

    Password recovery
    E-mail
    Login
    Register

    We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.